TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
CDMOs and CROs at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
51 CDMOs and CROs are at TIDES Europe 2026 — 23 presentations on the program and 50 with a booth in the exhibit hall. Most represented: Bachem (5 on the program), PolyPeptide Group (4 on the program), Axolabs (2 on the program). 50 of them have their own page in this guide. As of Nov 2, 2026.
Focus
Top represented
Showing 1–12 of 51 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Bachem Bubendorf, Switzerland | |
Contract development and manufacturing organization for peptide and oligonucleotide active pharmaceutical ingredients, from research quantities to commercial scale. | Booth Exhibiting at Booth 703 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 14:30–15:00 Beyond Packed Beds: Advancing Scalable Oligonucleotide Manufacturing Through Stirred-Bed Technology Building oligonucleotides in a continuously stirred reactor rather than a packed column, so reagents mix evenly and batches can reach ton scale. Talk Wed Nov 4 16:15–16:45 Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%. Talk Wed Nov 4 15:00–15:30 Dehydroascorbate: More Sustainable Disulfide Bond Formation in Peptide Manufacturing Using an oxidised form of vitamin C instead of harsh chemicals to form the sulfur bridges that hold many peptide drugs in shape. Talk Wed Nov 4 11:50–12:20 Digital Manufacturing in Practice: Enabling Efficient and Compliant Large-scale Production Running large-scale production on digital records and automation, and what that changed for output, consistency and the ability to spot process problems. CMC & Manufacturing Chair Thu Nov 5 08:00–08:05 |
PolyPeptide Group Baar, Switzerland | |
Contract development and manufacturing organization for peptide and oligonucleotide APIs, from clinical to commercial scale. | Booth Exhibiting at Booth 309 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 09:05–09:35 Strategies for Manufacturing of Long and Complex Peptides: Technical Considerations and Case Studies Ways to make long, sticky peptides at scale by mixing solid-support and solution methods and cutting solvent use, with real examples. Talk Wed Nov 4 14:00–14:30 Case Studies of Pre-clinical Development and IND Acceleration for Peptides Case studies on lining up early peptide process work, manufacturing plans and safety testing so a drug reaches first clinical trials sooner. |
Axolabs Kulmbach, Germany | |
Oligonucleotide contract research and manufacturing organization offering discovery, preclinical, analytical and GMP manufacturing services. | Booth Exhibiting at Booth 515 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 09:05–09:45 Chair Tue Nov 3 09:00–09:05 Workshop Moderators’ Introduction Which early manufacturing and quality decisions set what an oligonucleotide drug costs to produce, and when in development they should be taken. Talk Wed Nov 4 13:25–13:55 From Development Candidate Nomination to First-in-Human: Accelerating Oligonucleotide Development Through Integrated Strategies What it took to move a sugar-tagged siRNA candidate from selection to its first human trial on a tight schedule. OligonucleotidesCMC & Manufacturing |
Almac Craigavon, United Kingdom | |
Drug development services for small molecules and peptides, including analytical testing, API supply, radiolabelling, formulation and solid-state services. | Booth Exhibiting at Booth 620 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 11:00–11:30 Individualised Cancer Vaccines: Developing a High-throughput cGMP Peptide Manufacturing Philosophy How to make twenty different peptides to clinical quality in twenty days for one patient's personalised cancer vaccine, then do it again. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
Asymchem Tianjin, China | |
Contract development and manufacturing organization for small molecules, oligonucleotides and peptides, with flow chemistry and enzymatic process capabilities. | Booth Exhibiting at Booth 402 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 12:15–12:45 Innovating Oligonucleotide Production: Enzymatic Fragment Ligation for siRNA Joining short RNA fragments with enzymes in water instead of standard solid-phase steps, for purer siRNA at lower cost and larger scale. OligonucleotidesCMC & Manufacturing Talk Thu Nov 5 07:30–08:00 Advancing TIDES with Flow Chemistry How running peptide and oligonucleotide chemistry as a continuous flowing stream tightens control, improves safety and cuts waste. CMC & Manufacturing |
Contract development and manufacturing organization for peptides, oligonucleotides, lipids and complex APIs, with integrated drug product supply. | Booth Exhibiting at Booth 602 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 14:30–15:00 Accelerate Timeline to Start PhI: Phase Appropriate Development and Integrated Drug Product Supply Running peptide drug substance and finished-product development side by side to reach safety testing and the first human trial sooner. Chair Thu Nov 5 13:55–14:00 |
ST Pharm Seoul, South Korea | |
South Korean contract developer and manufacturer of oligonucleotide APIs, also producing phosphoramidites and offering mRNA services. | Booth Exhibiting at Booth 503 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 12:15–12:45 Engineered Cysteine AOC Process Development: DAR-Guided Fraction Pooling, DAR Blend-Validated Orthogonal Methods, and Conjugation Site Determination Ways to purify and measure antibody–oligonucleotide conjugates made on engineered cysteines, pooling fractions by how many oligonucleotides each antibody carries. OligonucleotidesCMC & Manufacturing |
Ajinomoto Bio-Pharma Services San Diego, CA | |
Contract development and manufacturing organization for oligonucleotides, peptides and biologics, offering AJIPHASE liquid-phase synthesis technology. | Booth Exhibiting at Booth 711 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 13:25–13:55 Addressing the Next Scale of Oligonucleotide Manufacturing: CMC Guided Transition from Solid Phase Synthesis to AJIPHASE® and Chemical Enzymatic siRNA Production Why one maker plans to move oligonucleotide production from solid-phase to liquid-phase chemistry, and how enzymes could join fragments at larger scale. OligonucleotidesCMC & Manufacturing |
BioSpring Frankfurt, Germany | |
Contract development and manufacturing organization for oligonucleotides, from research quantities to commercial GMP supply. | Booth Exhibiting at Booth 511 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 11:00–11:15 |
Catalent Somerset, NJ | |
Contract development and manufacturing organization for drug products, including oral delivery technologies and injectable formulation and fill-finish. | Booth Exhibiting (no floor booth listed) Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 12:30–12:50 Advancing Beyond Injections: Technologies Driving Oral Delivery of Peptides Ways to get peptide drugs absorbed when swallowed rather than injected, using fatty carriers, slow-release capsules and the lining of the mouth. PeptidesDiscovery & Clinical |
Nitto Avecia Milford, Massachusetts | |
Contract developer and manufacturer of oligonucleotide APIs, from process development through commercial GMP production. | Booth Exhibiting at Booth 413 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 16:15–16:45 On-Resin Chemical Ligation for Next-generation siRNA Manufacturing A chemical way to join siRNA strand pieces while they are still on the solid support, developed alongside enzyme-based joining. |
WuXi TIDES Shanghai, China | |
WuXi AppTec's integrated contract development and manufacturing platform for oligonucleotides, peptides and related conjugates. | Booth Exhibiting at Booth 704 Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 07:30–08:00 Overcoming Scale-Up Barriers: Ensuring Robust CMC for Next-Gen Peptide and Oligonucleotide Drugs Which manufacturing and quality choices decide whether a complex looped or chemically linked peptide drug can still be made at full scale. CMC & Manufacturing |
Find buyers from CDMOs and CROs
Tell us what you sell and we’ll find the people at these CDMOs and CROs most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse TIDES Europe 2026 by
Organization type
Focus
Exhibit hall
Everyone
Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction